UCB SA (EBR:UCB)
181.80
+2.30 (1.28%)
Feb 21, 2025, 5:35 PM CET
UCB SA Revenue
UCB SA had revenue of 2.79B EUR in the half year ending June 30, 2024, a decrease of -2.24%. This brings the company's revenue in the last twelve months to 5.45B, up 3.32% year-over-year. In the year 2023, UCB SA had annual revenue of 5.18B, down -4.87%.
Revenue (ttm)
5.45B
Revenue Growth
+3.32%
P/S Ratio
6.33
Revenue / Employee
606.00K
Employees
9,083
Market Cap
34.49B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.18B | -265.00M | -4.87% |
Dec 31, 2022 | 5.45B | -330.00M | -5.71% |
Dec 31, 2021 | 5.78B | 430.00M | 8.04% |
Dec 31, 2020 | 5.35B | 434.00M | 8.83% |
Dec 31, 2019 | 4.91B | 281.00M | 6.07% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
argenx SE | 1.71B |
Fagron NV | 820.76M |
Ion Beam Applications | 465.75M |
Nyxoah | 5.08M |
Onward Medical | -188.00K |
Hyloris Pharmaceuticals | 6.94M |
Sequana Medical NV | 433.50K |
Biocartis Group NV | 60.82M |
UCB SA News
- 4 weeks ago - United Community Banks, Inc. (UCB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - United Community Banks Non-GAAP EPS of $0.63 beats by $0.07, revenue of $239.47M misses by $3.26M - Seeking Alpha
- 5 weeks ago - UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx) - Benzinga
- 7 weeks ago - United Community Banks Inc (UCB) Announces Upcoming Fourth Quarter 2024 Financial Results Release - GuruFocus
- 2 months ago - United Community Banks to acquire ANB Holdings in an all-stock deal - Seeking Alpha
- 3 months ago - Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside - Benzinga
- 3 months ago - FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease - Benzinga
- 3 months ago - UCB gets FDA approval for Bimzelx for hidradenitis suppurativa - Seeking Alpha